Aurobindo Pharma's revenue grew 22% on a YoY basis to `5270 crs. in Q3. Growth was led by all business segments and markets. US and growth markets reported growth of 27% and 36% respectively on a YoY basis. Consolidated EBITDA increased to `1,086 Cr vs. `1,025 Cr in Q3 last year, an increase of...